David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies. In this Q&A conversation, the Eye Care Network ...

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care. This year in retina is almost ...

CoTx-10 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Coave Therapeutics has announced its lead gene ...

Catch up on this week's highlights in retina. Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...

David S. Liao, MD, PhD | Authors | Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.

Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor. Michael Lai, MD, PhD, presented at the 2025 annual scientific meeting of the American ...

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025. To strengthen Opus Genetics’ gene therapy program ...